Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Ordinary Shares, nominal value 0.05 GBP per share
-
Shares outstanding
-
84,213,667
-
Total 13F shares
-
35,736,138
-
Share change
-
+1,034,121
-
Total reported value
-
$246,007,905
-
Put/Call ratio
-
122%
-
Price per share
-
$7.00
-
Number of holders
-
34
-
Value change
-
+$8,102,449
-
Number of buys
-
16
-
Number of sells
-
7
Institutional Holders of Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share (VRNA) as of Q4 2020
As of 31 Dec 2020,
Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share (VRNA) was held by
34 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
35,736,138 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, NEA Management Company, LLC, RA CAPITAL MANAGEMENT, L.P., Vivo Capital, LLC, PERCEPTIVE ADVISORS LLC, Novo Holdings A/S, Abingworth LLP, Polar Capital Holdings Plc, Aisling Capital Management LP, and WELLINGTON MANAGEMENT GROUP LLP.
This page lists
34
institutional shareholders reporting positions in this security
for the Q4 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.